Novogen Names John O'Connor as Chairman

Novogen Limited NVGN, announced today the appointment of a new Chairman, Mr John O'Connor, and new Deputy Chairman, Mr Bryce Carmine, effective immediately. Incoming CEO, Dr James Garner, has also been formally appointed to the Board as an Executive Director and former Acting CEO, Mr Iain Ross, will resume his role on the Board as a Non-Executive Director. Mr O'Connor has been Deputy Chairman since 2014 and takes over from Mr Ian Phillips MNZM who was appointed Interim Chairman in July 2015. Based in Sydney and a long-term shareholder in Novogen, Mr O'Connor has more than 30 years' experience in the financial industry, having held numerous management roles as a fund manager and stockbroker. In thanking Mr Phillips for his contribution as Interim Chairman over the past seven months, Mr O'Connor said: "Ian took over as Chairman at a time when the Company was undergoing a period of transition and he has been instrumental in leading the Company to the point where we have a clear strategy in place. I am pleased Ian has agreed to remain on the Board as he brings invaluable experience and contacts that we can call upon as we build the Company going forward." Mr Phillips said: "I am very proud to have led the Company through this transition phase. We now have a strong Board and Management Team in place. I want to thank Iain, who as Acting CEO, has worked tirelessly behind the scenes with the Management Team and who was instrumental in helping us attract James Garner as our permanent CEO. Both Iain and I intend to remain as active Board members and look forward to playing our part in building Novogen." In line with ASX requirements, Mr O'Connor's appointment as Chairman means he will step down as Chair of the Company's Audit, Risk and Governance Committee, effectively immediately. The composition of the Committee will now be Mr Bryce Carmine as Chair; Prof Peter Gunning as member; and Mr Ian Phillips as member. About John O'Connor Mr John O'Connor, BEC, MAICD has more than 30 years' experience in the financial industry and was appointed to the Novogen Board in May 2012. During his career, he has held numerous management roles as a fund manager and stockbroker in the UK, US and Australia as well as a partnership in a securities business. He has been a consultant to several biotech companies, including Novogen Limited and Marshall Edwards Inc., and has assisted with fundraising. Mr O'Connor served on the Board of Lonsec Securities, a Zurich Insurance-owned business for several years. About Bryce Carmine Mr Bryce Carmine has 36 years' experience with one of the world's largest pharmaceutical companies where he held numerous roles including Executive Vice President for Eli Lilly & Co, and President, Lilly Bio-Medicines business unit. For much of that time, as a senior executive, he was responsible for Eli Lilly's global late-stage drug development pipeline. Mr Carmine holds US residency and brings to the Board a strong understanding of the drug development process and dynamics of the pharmaceutical industry. He will continue to Chair the Board's Scientific Committee. Mr Carmine is currently Chairman and CEO of a Sydney-based biotechnology company, HaemaLogiX. He holds a B.Sc. in biochemistry from Massey University in New Zealand.